A Multicenter Evaluation of Methods to Reduce Hyperemia Associated With Bimatoprost Therapy for Glaucoma or Ocular Hypertension

Innovative Medical

Overview

Evaluate the incidence of hyperemia in patients using bimatoprost and to determine if simple interventions reduce its incidence and to assess the value of detailed instruction in increasing patient compliance and willingness to continue bimatoprost therapy, despite the occurrence of hyperemia.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Masking

NONE

Conditions

Glaucoma

Interventions

BimatoprostDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * · Male or female \> 18 years of age * No prior use of bimatoprost * Diagnosis of open-angle glaucoma or ocular hypertension * Ability to provide informed consent and likely to complete all study visits Exclusion Criteria: * · Known contraindication to bimatoprost * Uncontrolled systemic disease * Active ocular disease other than glaucoma or ocular hypertension * Required use of ocular medications other than the study medications during the study (intermittent use of artificial tear solutions will be permitted) * History of intraocular surgery within the last 3 months

Locations (1)

Dr. Noecker

Pittsburgh, Pennsylvania, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.